Melanoma
📧 Sign up to get email alerts when something new happens for Melanoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma [EARLY_Phase 1]
A clinical trial update indicates a study of FUSA with intratumoral PolyICLC for regionally advanced resectable melanoma is in early Phase 1…
-
CLINICAL_TRIALS trial_result · 2025-11-20Clinical Trial Update: Tracing Dissemination of Melanoma Cells in Healthy Tissues
A completed clinical trial investigating the dissemination of melanoma cells into healthy tissues. The study is sponsored by Assistance Publ…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)
A retrospective observational study examining long-term safety and outcomes in pediatric melanoma patients treated with ipilimumab within th…
-
CLINICAL_TRIALS trial_result · 2025-11-19Clinical Trial Update: Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma [Phase 1, Phase 2]
This document updates on a Phase 1/2 clinical trial assessing different doses of BI-1607 in combination with pembrolizumab and ipilimumab fo…
-
CLINICAL_TRIALS trial_result · 2025-11-19Clinical Trial Update: High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies [NA]
A clinical trial is evaluating high dose-rate brachytherapy for unresectable primary and metastatic liver malignancies. The study is current…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: Circulating Tumor Cells and Melanoma: Comparing the EPISPOT and CellSearch Techniques
A completed clinical trial evaluating circulating tumor cell detection methods EPISPOT and CellSearch in patients with metastatic melanoma.
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: Mirdametinib in Patients With Advanced NF1-mutant Melanoma [Phase 2]
Phase 2 clinical trial evaluating Mirdametinib in patients with advanced or metastatic NF1-mutant melanoma is currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation [NA]
Massachusetts General Hospital describes using serial plasma NGS as a new efficacy metric to guide immunotherapy treatment discontinuation. …
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Ovarian Reserve and Semen Parameters Evolution During Adjuvant Therapy in Melanoma
Investigates how adjuvant therapy for melanoma affects ovarian reserve and semen parameters. The study tracks reproductive hormones and seme…
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Development of an Aid to Melanoma Detection Using Artificial Intelligence Algorithms Based on Images From the VECTRA 3D System. [NA]
A clinical trial is developing an AI-based tool to aid melanoma detection using VECTRA 3D skin images. The study is currently not recruiting…
-
CLINICAL_TRIALS trial_result · 2025-11-17Clinical Trial Update: Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies [Phase 1]
This clinical trial update notes the termination of a Phase 1 study of BDC-3042 as a single agent and in combination with cemiplimab in pati…
-
EMA approval · 2025-11-13EMA Authorised: Mekinist (trametinib) — Novartis Europharm Limited
The EMA authorised Mekinist (trametinib) for melanoma; the marketing authorisation holder is Novartis Europharm Limited.
-
CLINICAL_TRIALS other · 2025-11-13Clinical Trial Update: A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) [Phase 1]
Phase I, open-label multicenter trial evaluating safety, tolerability, and pharmacokinetics of selumetinib (AZD6244) in cancer patients; cur…
-
CLINICAL_TRIALS trial_result · 2025-11-12Clinical Trial Update: Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab
Real-world outcomes in melanoma patients treated with neoadjuvant nivolumab+relatlimab versus nivolumab+ipilimumab; the study is completed a…
-
CLINICAL_TRIALS trial_result · 2025-11-12Clinical Trial Update: A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer [Phase 1, Phase 2]
This document details an ongoing Phase 1/2 clinical trial evaluating cobolimab in combination with dostarlimab in pediatric and young adult …
-
CLINICAL_TRIALS research · 2025-11-12Clinical Trial Update: Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial [Phase 2]
Phase 2 trial evaluating time-of-day specified immunotherapy for advanced melanoma; currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-12Clinical Trial Update: Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. [Phase 2, Phase 3]
A Phase 2/3 clinical trial evaluating EIK1001 in combination with pembrolizumab versus placebo with pembrolizumab as first-line therapy in a…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases [Phase 1]
Phase 1 study evaluating aerosolized gemcitabine for treatment of various solid tumors, including those with pulmonary metastases; recruitme…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma [NA]
A clinical trial evaluating whether lymphovenous bypass performed before axillary lymph node surgery can reduce the risk of lymphedema in pa…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
A clinical trial is evaluating an educational tool to help melanoma patients with pre-existing autoimmune diseases who are candidates for im…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Molecular Analysis of Childhood and Adolescent Melanocytic Lesions
A study investigating molecular features of childhood and adolescent melanocytic lesions is currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab [Phase 1, Phase 2]
Clinical trial update for ARRY-614 in combination with nivolumab or nivolumab plus ipilimumab (Phase 1/2) currently active and not recruitin…
-
CLINICAL_TRIALS trial_result · 2025-11-06Clinical Trial Update: Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab [Phase 2]
A Phase 2 melanoma trial is investigating adjuvant treatment decisions based on pathological response to neoadjuvant nivolumab. The study in…
-
EMA approval · 2025-11-05EMA Authorised: Mektovi (binimetinib) — Pierre Fabre Medicament
The European Medicines Agency has authorised Mektovi (binimetinib) for melanoma, with Pierre Fabre Medicament as the marketing authorization…
-
EMA approval · 2025-11-05EMA Authorised: Braftovi (Encorafenib) — Pierre Fabre Medicament
The EMA authorised Braftovi (encorafenib) for melanoma and colorectal cancer. Pierre Fabre Medicament is the marketing authorization holder.